New Therapeutic Approaches to Combat Arterial Thrombosis

Figure 3
Figure 3 Structures for the reversible P2Y12 antagonists currently in clinical trials

The varied structures of (A) ticagrelor, (B) cangrelor, and (C) elinogrel are shown. All three drugs share the same molecular target, the platelet P2Y12 receptor.

This Article

  1. MI April 2011 vol. 11 no. 2 111-123